Home › Blood Clots › NCT07363525

Michigan Initial Experience Using Tigertriever for Thrombectomy

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Patients admitted with large vessel occlusion (LVO) and treated with the Tigertriever, as per the approved indication.
2. Tigertriever was used as the first line treatment in the target vessel.
3. A signed informed consent.
4. Age ≥ 18.

Exclusion Criteria:

-1. Evidence of acute brain hemorrhage on NCCT or MR at admission. 2. Prior hemorrhage, stroke, thrombolysis, and/or endovascular therapy in the last 3 months.

3\. pre-stroke disability (pre-stroke mRS ≥ 2).

About the study

The purpose of this research study is to collect data about the effectiveness (i.e. how the device works) and safety (how safe it is to use such a device) of the Tigertriever in restoring blood flow by removing thrombus (or blood clot) from a large intracranial vessel (blood vessel in the brain) in patients experiencing ischemic stroke within 8 hours of symptom onset.

What is being tested

• Mechanical Thrombectomy (procedure)

Sponsor: Henry Ford Health System · Participants: 150 · Started: Jan 15, 2026

Contact the study team

• Alex Chebl, MD · Phone: 313-916-2644
• Kelly Tundo, RN · Phone: 313-916-1102

Official record on ClinicalTrials.gov — NCT07363525

Locations in the U.S.

Conditions

• Blood Clots
• Ischemic Stroke
• Stroke

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.